EA201391733A1 - Каннабиноиды, применяемые для лечения невропатической боли - Google Patents

Каннабиноиды, применяемые для лечения невропатической боли

Info

Publication number
EA201391733A1
EA201391733A1 EA201391733A EA201391733A EA201391733A1 EA 201391733 A1 EA201391733 A1 EA 201391733A1 EA 201391733 A EA201391733 A EA 201391733A EA 201391733 A EA201391733 A EA 201391733A EA 201391733 A1 EA201391733 A1 EA 201391733A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cannabinoids
neuropathic pain
treatment
cannabinoids used
cannabichromen
Prior art date
Application number
EA201391733A
Other languages
English (en)
Inventor
Сабатино Майоне
Франческо Росси
Джеффри Гай
Колин Стотт
Тецуро Кикути
Original Assignee
ДжиДаблЮ ФАРМА ЛИМИТЕД
Оцука Фармасьютикал Ко. Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДжиДаблЮ ФАРМА ЛИМИТЕД, Оцука Фармасьютикал Ко. Лимитед filed Critical ДжиДаблЮ ФАРМА ЛИМИТЕД
Publication of EA201391733A1 publication Critical patent/EA201391733A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к каннабиноидам, применяемым для лечения невропатической боли. Предпочтительно указанные каннабиноиды представляют собой один или несколько каннабиноидов, выбранных из группы, включающей каннабигерол (CBG), каннабихромен (СВС), каннабидиварин (CBDV) или тетрагидроканнабиварин (THCV). Более предпочтительно указанные каннабиноиды выделяют или получают очисткой из экстрактов растения конопли.
EA201391733A 2011-05-20 2012-05-18 Каннабиноиды, применяемые для лечения невропатической боли EA201391733A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1108506.5A GB2491118B (en) 2011-05-20 2011-05-20 Cannabinoids for use in the treatment of neuropathic pain
PCT/GB2012/051129 WO2012160358A1 (en) 2011-05-20 2012-05-18 Cannabinoids for use in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
EA201391733A1 true EA201391733A1 (ru) 2014-04-30

Family

ID=44279366

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391733A EA201391733A1 (ru) 2011-05-20 2012-05-18 Каннабиноиды, применяемые для лечения невропатической боли

Country Status (21)

Country Link
US (1) US9895342B2 (ru)
EP (1) EP2709604B1 (ru)
JP (1) JP6147249B2 (ru)
KR (1) KR20140037124A (ru)
CN (1) CN103533930A (ru)
AR (1) AR086398A1 (ru)
AU (1) AU2012260611B2 (ru)
BR (1) BR112013029773A2 (ru)
CA (1) CA2833099C (ru)
CO (1) CO6811867A2 (ru)
DK (1) DK2709604T3 (ru)
EA (1) EA201391733A1 (ru)
ES (1) ES2624308T3 (ru)
GB (2) GB2491118B (ru)
IL (1) IL229474B (ru)
MX (1) MX2013013141A (ru)
PT (1) PT2709604T (ru)
SG (1) SG194839A1 (ru)
TW (1) TW201249425A (ru)
WO (1) WO2012160358A1 (ru)
ZA (1) ZA201309364B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3478307A4 (en) 2016-06-29 2020-02-26 Cannscience Innovations Inc. DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. METHOD AND COMPOSITIONS FOR TREATING REST-FREE LEG SYNDROME
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
EP3684353A4 (en) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
WO2019147690A1 (en) * 2018-01-23 2019-08-01 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
AU2020268218B2 (en) * 2019-05-03 2022-09-08 Zyus Life Sciences Inc. Formulation for pain management
EP4138813A4 (en) * 2020-04-24 2024-05-15 Zyus Life Sciences Inc CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN116648241A (zh) * 2021-04-14 2023-08-25 成都百裕制药股份有限公司 氘代苯酚衍生物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000976B1 (ru) 1996-03-25 2000-08-28 Эли Лилли Энд Компани Композиция для снятия боли и способ снятия боли
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
KR101008609B1 (ko) 2002-08-14 2011-01-17 지더블유 파마 리미티드 점막투여용 칸나비노이드 액체 제형
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
EP1747786A3 (en) 2005-07-25 2007-04-25 Perdix Eurogroup S.L. Natural product in cream with anti-vitiligo therapeutic properties
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2517313A1 (en) * 2005-08-26 2007-02-26 Queen's University At Kingston Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors

Also Published As

Publication number Publication date
GB2524689A (en) 2015-09-30
WO2012160358A1 (en) 2012-11-29
JP2014513715A (ja) 2014-06-05
GB2524689B (en) 2016-01-27
ZA201309364B (en) 2015-04-29
CA2833099A1 (en) 2012-11-29
ES2624308T3 (es) 2017-07-13
CA2833099C (en) 2020-11-03
AU2012260611A1 (en) 2013-12-12
IL229474B (en) 2018-11-29
JP6147249B2 (ja) 2017-06-14
TW201249425A (en) 2012-12-16
IL229474A0 (en) 2014-01-30
US20140378539A9 (en) 2014-12-25
AR086398A1 (es) 2013-12-11
DK2709604T3 (en) 2017-05-15
GB201108506D0 (en) 2011-07-06
CO6811867A2 (es) 2013-12-16
US20140107192A1 (en) 2014-04-17
EP2709604A1 (en) 2014-03-26
CN103533930A (zh) 2014-01-22
NZ618246A (en) 2016-01-29
SG194839A1 (en) 2013-12-30
BR112013029773A2 (pt) 2017-01-17
AU2012260611B2 (en) 2017-06-15
KR20140037124A (ko) 2014-03-26
EP2709604B1 (en) 2017-02-01
MX2013013141A (es) 2014-02-17
GB2491118A (en) 2012-11-28
GB2491118B (en) 2015-12-30
PT2709604T (pt) 2017-05-17
GB201512357D0 (en) 2015-08-19
US9895342B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
EA201391733A1 (ru) Каннабиноиды, применяемые для лечения невропатической боли
EA201490711A1 (ru) Фармацевтическая композиция, содержащая фитоканнабиноиды каннабидиварин (cbdv) и каннабидиол (cbd)
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
UA108852C2 (ru) Применение одного или комбинации фито каннабиноидов для лечения эпилепсии
NZ602925A (en) Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
CO2019014279A2 (es) Proceso para la purificación y separación de cannabinoides a partir de cáñamo seco y hojas de cannabis
FI3743053T3 (fi) Kannabinoidien käyttö epilepsian hoidossa
GT200900183A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CO2020009747A2 (es) Métodos para purificar cannabinoides usando cromatografía líquido-líquido
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
BR112013019522A2 (pt) dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino
GB201120067D0 (en) Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
GT200900062A (es) Nuevos compuestos de diosmetina, un proceso para su preparacion y las composiciones farmaceuticas que los contienen
IL283034A (en) Cannabis plants with a cannabinoid profile enriched for delta-9-tetrahydrocannabinol, cannabigerol and tetrahydrocannabiuria
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
NZ730985A (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
CL2015000434A1 (es) Metodo para el tratamiento, prevencion o disminucion de la severidad de una condicion o trastorno no neoplasico de la piel que comprende administrar un compuesto derivado de retinoides; composicion dermica que comprende los derivados de retinoide.
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
AR119043A1 (es) Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides
BR112015010186A2 (pt) sulfonamida cíclica contendo derivados como inibidores da via de sinalização de hedgehog
BR112014007922A2 (pt) nanocápsulas de oxoisoaporfinas para o tratamento da depressão
MX2022004888A (es) (-)-cis tetrahidrocannabinol ((-)-cis-thc) para uso como medicamento.
TH153696A (th) การใช้ไฟโตแคนนาบินอยด์หรือสารผสมของสารดังกล่าวในการรักษาโรคลมบ้าหมู